 |
|
|
Emmet Keeffe
Academic Appointments
Appointment
Organization
Emeritus (Active) Professor
Graduate & Fellowship Program Affiliations
|
|
|
Honors & Awards
Title
Organization
Date(s)
Honorary Fellow
Royal College of Physicians of Ireland
2006
Fellow
American Gastroenterological Association
2006
Fellow
American Society for Gastrointestinal Endoscopy
2006
Master
American College of Physicians
2006
Biographee
Who's Who in the World
2006
Administrative Appointments
Title
Organization
Start Year
End Year
Board of Directors
Foundation for Digestive Health and Nutrition
2004
-
Chief of Hepatology
Stanford University School of Medicine
2000
2007
Co-Director, Liver Transplant Program
Stanford University Medical Center
2000
2007
Chief of Clinical Gastroenterology
Stanford University School of Medicine
1995
2000
Medical Director, Liver Transplant Program
Stanford University Medical Center
1995
2000
Professional Education
Degree
Awarding Institution
Field of Study
Year of Graduation
Fellowship
UCSF
Hepatology
1979
Fellowship
Oregon Health & Science Univ
Gastroenterology
1974
Residency
Oregon Health & Science Univ
Internal Medicine
1973
M.D.
Creighton University
Medicine
1969
B.S.
University of San Francisco
Biology
1964
Research Interests
My primary current clinical research interests are focused on treatment of chronic hepatitis C with nitazoxanide as well as treatment of chronic hepatitis B, application of hepatitis vaccination especially in patients with chronic liver disease, and selection and outcomes of liver transplantation. In the past, I and my colleagues have studied the role of standard interferon, interferon alfacon-1, and peginterferon alone or with ribavirin for the treatment of chronic hepatitis C. We have also documented the role of liver transplantation for fulminant hepatic failure associated with mushroom poisoning, reviewed the institutional results of new liver transplant programs, reported a variant of recurrent hepatitis B after liver transplantation called fibrosing cholestatic hepatitis, documented that the results of liver transplantation in Asian patients with chronic hepatitis B are the same as the transplant outcomes of non-Asians, assessed the quality of life following liver transplantation using a comprehensive profile of psychologic testing, reviewed selection criteria and outcomes of liver transplantation for the controversial indications, defined criteria for liver transplantation and associated comorbidities in patients with alcoholic liver disease, proposed minimal listing criteria for liver transplantation, and wrote several textbook chapters on selection of patients for liver transplantation.
I have been a principle investigator in multiple clinical trials using various interferons, combined interferon or peginterferon plus ribavirin, and nitazoxanide for the treatment of chronic hepatitis C, antiviral trials using lamivudine and famciclovir for the treatment of chronic hepatitis B, optimal management of hepatatis B patients after liver transplantation, and trials of hepatitis B and hepatitis A vaccines. I reported that hepatitis A and B is more severe in patients with chronic liver disease, and demonstrated in an international trial the safety and efficacy of hepatitis A and B vaccine in patients with chronic liver disease.
Publications
-
Keeffe EB,
Marcellin P
"New and Emerging Treatment of Chronic Hepatitis B."
Clin Gastroenterol Hepatol
2007;
More »
-
Morgan M,
Park W, Keeffe EB
"Diagnosis and treatment of chronic hepatitis B: an update."
Minerva Gastroenterol Dietol
2007;
53:
1:
25-41
More »
-
Arora G,
Keeffe EB
"Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy."
Rev Gastroenterol Disord
2007;
7:
2:
63-73
More »
-
Ahmed A,
Keeffe EB
"Current indications and contraindications for liver transplantation."
Clin Liver Dis
2007;
11:
2:
227-47
More »
-
Keeffe EB,
Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F
"Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B."
Clin Gastroenterol Hepatol
2007;
More »
